Literature DB >> 3056420

Autoantibodies to intracellular proteins in human systemic lupus erythematosus are not due to random polyclonal B cell activation.

A E Gharavi1, J L Chu, K B Elkon.   

Abstract

Antibody binding to total protein extracted from a mammalian source (HeLa cells) and from a prokaryotic source (Escherichia coli) was compared in sera from patients with systemic lupus erythematosus (SLE) and sera from normal subjects. When the average numbers of peptides or proteins recognized by IgG antibodies were compared on immunoblots, SLE sera bound to a significantly greater number of proteins from the HeLa cell extract than did sera from normal individuals (P less than 0.001). In contrast, SLE sera actually bound to fewer E coli proteins than did the sera obtained from normal controls, although the difference was not statistically significant. There was no correlation between the number of E coli proteins and HeLa proteins recognized by individual SLE sera, and there was no trend toward reactivity with a larger number of antigens in sera containing higher levels of IgG. IgG from SLE sera did not bind to 6 purified eukaryotic protein standards (selected solely on the basis of differences in size and charge) either in their denatured state or in their native state. These findings indicate that the high levels of IgG antibodies against selected eukaryotic intracellular proteins in patients with SLE cannot be explained by a random polyclonal B cell activation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056420     DOI: 10.1002/art.1780311101

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful.

Authors:  Tri Giang Phan; Richard C W Wong; Stephen Adelstein
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

2.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.

Authors:  M Koshy; D Berger; M K Crow
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Inhibiting effect of charged polymers on interaction of human lupus autoantibodies with certain intracellular proteins.

Authors:  A E Kabakov; L N Brovkina; A M Poverenny; L Cebecauer
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

4.  Analysis of autoantibodies to recombinant La (SS-B) peptides in systemic lupus erythematosus and primary Sjogren's syndrome.

Authors:  P Bini; J L Chu; C Okolo; K Elkon
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

Review 5.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

6.  Quantification of cross-reactive idiotype-positive rheumatoid factor produced in autoimmune rheumatic diseases. An indicator of clonality and B cell proliferative mechanisms.

Authors:  F Shokri; R A Mageed; G D Kitas; P Katsikis; H M Moutsopoulos; R Jefferis
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

7.  Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus.

Authors:  N Suzuki; T Sakane; E G Engleman
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies.

Authors:  F W Miller; S A Twitty; T Biswas; P H Plotz
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

Review 9.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

10.  Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.

Authors:  M S Atta; K L Lim; D A Ala'deen; R J Powell; I Todd
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.